Summary Report of Consolidated Financial Results
For the Nine Months Period ended December 31, 2010

February 10, 2011
Company name: NIPRO CORPORATION
TSE/OSE–1st section
Code No.8086
URL: http://www.nipro.co.jp/
Representative: Minoru Sano, President and Representative Director
Contact person: Akihiko Yamabe, Director and General Manager of Accounting Division
TEL: (06) 6372-2331
Filling date of quarterly reporting: February 14, 2011
Payment date of cash dividends: N/A
Supplemental material on quarterly reporting: None
Presentation on quarterly results: No(Note: Amounts are truncated to one million yen)
1. Consolidated results for the Nine months ended December 31, 2010 (From April 1, 2010 to December 31, 2010)(1) Consolidated results of operations(Note: % of change from the same period a year ago)

Operating
IncomeNet Sales
Millions of yen

145,223
133,063

9 months ended Dec. 31,2010
9 months ended Dec. 31,2009

%

9.1
(1.1)

Earnings per Share
9 months ended Dec. 31,2010
9 months ended Dec. 31,2009

Ordinary Income

Millions of yen

14,286
14,767%

Millions of yen

(3.3)
35.4

9,959
12,503Net Income%

Millions of yen(20.3)
98.8

4,002
6,352

%

(37.0)
137.9

Diluted Earnings per share

Yen

Yen

63.12
100.1556.93-(2) Consolidated Financial Position

Total Assets

Net Assets

Millions of yen

Millions of yen

406,286
383,396

116,118
116,070

9 months ended Dec. 31,2010
Year ended March 31, 2010

Note: Equity ９ months ended Dec. 31, 2010 113,536 million yen

Net Assets per
Share

Equity Ratio
%

Yen

27.9
29.8

Year ended March 31, 2010

1,790.17
1,802.33
114,309 million yen

2. Dividends
Annual dividends per shareFirstquarter

Secondquarter
Yen-

Year ended March 31, 2010
Year ending March 31, 2011
Year ending March 31, 2011
(Forecast)Thirdquarter
Yen

Year-end
Dividends
Yen

Yen

23.50
18.50

Annualdividends
Yen

-

29.50

53.00

-

22.50

41.00

Note: Whether the forecast of cash dividends has been revised in the current quarter or not: No

3. Forecast of Consolidated Financial Results for the Year ending March 31, 2011 (From April 1, 2010 to March 31, 2011)(Note: The % display shows increase/decrease ratio against the year ended March 31, 2010)
Operating
Ordinary
Earnings
Net Sales
Net Income
per Share
IncomeIncomeYear ending March 31, 2011

Millionsof yen%Millionsof yen%Millionsof yen%Millionsof yen%Yen

200,000

12.5

17,200(4.9)

12,100(18.8)

4,950(31.7)

78.05

Note: Whether the forecast of consolidated financial results has been revised in the current quarter or not: No

4. Others (For details, please refer to “2. Other information” on page 4 of attached materials.)(1) Change in significant subsidiaries during the current period: No(Note) Change in specified subsidiaries during the period that caused a change in the scope of consolidation(2) Adoption of accounting treatments simplified or unique for preparation: Yes(Note) Adoption of accounting treatments simplified and unique for preparation of quarterly consolidated financial
statements(3) Changes in accounting principles, procedures or presentation for consolidated financial statements[1] Changes by a newly issued accounting pronouncement: Yes[2] Changes other than [1]: No(Note) Changes in significant accounting principles, procedure and presentation which are to be stated in “Change insignificant matter of basis of preparation for consolidated financial statements”(4) Issued shares (Common stock)[1] Number of issued shares at end of the period (Including treasury stock):
9 months ended Dec. 31, 2010: 63,878,505 sharesYear ended March 31, 2010: 63,878,505 shares[2] Number of treasury stock at end of the period:
9 months ended Dec. 31, 2010: 456,228 sharesYear ended March 31, 2010: 455,328 shares[3] Average number of shares during the period:
9 months ended Dec. 31, 2010: 63,422,787 shares
9 months ended Dec. 31, 2009: 63,426,103shares*Information regarding the quarterly review procedure
This report is exempt from quarterly review procedure based on the Financial Instruments and Exchange Act. The review
procedure has been finished at the time of disclosure of this report.

*Disclaimer regarding projection information including appropriate use of forecasted financial results, and other special notes
The projection figures shown above are based on information that was available at the time of preparation and may containcertain uncertainties. Actual performance and other factors may differ from these projections due to changes in circumstancesand other developments. More information concerning these forecasts can be found in P.4 “1. Qualitative information for thenine months period ended December 31, 2010, (3) Qualitative information concerning forecast of consolidated financial
results” in the attachments.

Table of contents of attached materials

1. Qualitative information for the nine months period ended Dec. 31, 2010
(1)Qualitative information concerning consolidated financial results(2)Qualitative information on the consolidated financial position(3)Qualitative information concerning forecast of consolidated financial results

P.2
P.2
P.3
P.4

2. Other information(1)Overview of changes in significant consolidated subsidiaries(2)Overview of accounting treatments simplified or unique for preparation(3)Overview of changes in accounting principles, procedures, and disclosure for preparation

P.4
P.4
P.4
P.5

3. Consolidated financial statements(1)Quarterly consolidated balance sheets(2)Quarterly consolidated statements of income(3)Quarterly consolidated statements of cash flows(4)Notes related to going concern(5)Segment information(6)Notes to statements of shareholders’ equity, if having significant variation

P.7
P.7
P.9
P.10
P.12
P.12
P.15

-1-

1. Qualitative information for the nine months period ended December 31, 2010
(1) Qualitative information concerning consolidated financial results
During the nine months period ended December 31, 2010, despite the emerging countries could enjoy
steady economic progress, the whole world economy could not take such trends as granted because there
were slowdown in the U.S. and European economies. The Japanese economy could avert a recession thanks
to the exports to Asia and emergency economic package, but there still remains the uncertainty about therecovery due to the concern about expiration of policy effects and the sharp appreciation of yen.
Under such circumstances, we aimed to expand sales and production, improve business efficiency andpromoted manufacturing in each location on the basis of local production for local consumption, all of whichhave been strived by us to improve our business performance.
Therefore, we grew each business and the consolidated sales in this nine months period increased 9.1%
compared with the same period a year ago to 145,223 million yen.
However, as for the profit, consolidated operating income decreased 3.3% compared with the same period ayear ago to 14,286 million yen mainly due to the increase of selling, general and administrative expenses.
Ordinary income decreased 20.3% compared with the same period a year ago to 9,959 million yen mainly due
to the increase of non-operating expenses. Net income decreased 37.0% compared with the same period ayear ago to 4,002 million yen.
The overviews of the results by segment in the current period are as follows.
[1] Medical businessOn the domestic side of medical business, our business and market conditions remained severe by the
reduction of official reimbursement price of drug and special treatment materials. Under such circumstances,
we have aimed to expand our market share aggressively and improved sales efficiency.
Sales grew greatly in vascular-related products (such as blood-clot trapping catheters, coronary artery stentand angiographic kit). In addition, sales of high-value-added products which can prevent malpractice andreduce infection risks, enteral alimentation-related products, ecologically friendly products, dialysis related
products (such as blood tube and dialysis solution) and testing-related products like glucose analysis device
grew steadily and made a profit.
On the international side of the business, we had great impact by more advancing appreciation of Japanese
yen against the U.S. dollar and Euro in the foreign exchange market. However, we continued active sales
promotion in Asian market where the economy is significantly growing, and strengthened the community-based
sales promotion in Latin American and European market so as to increase the sales amount.
Sales grew greatly in diabetic-related products, as well as the sales in dialysis-related product (such as
dialyzer, dialysis machine and blood tube) by means of our active sales promotions in the dialysis market suchas in China and oxygenator increased steadily
As a result, net sales of the business were 98,150 million yen.
[2] Pharmaceutical businessIn pharmaceutical business, we can divide into two categories; one is generic drug business whose mission isto provide low price and high quality drugs, and the other is contract manufacturing business where we havecapacities to produce various drugs and to offer high value added solutions against customer needs.
On the sales of generic drug, under governmental policy calling for the dissemination of generic products as‘generic drug share in quantity shall be expanded more than 30% until end of year 2012’, the raising up ofadditional points against dispensing of generic drug has been implemented since April 2010. Thus, while themarket is in underlying expansion, we have proactively promoted selling to dispensing pharmacy group to
result order increasing in sales of oral drug and drug for external use. In addition, injectable drug sales of ourmain product grew steadily as a result of new launching goods which are admitted as long term listing drug at
November 2010 and our detailed information service mainly to the hospitals subjected to the DPC system(Diagnostic Procedure Combination; comprehension payment system of medical cost for acute hospitalization).
-2-

Though we could not avoid the sales decrease by drug price revision (scheduled biyearly), we registeredsignificant sales growth at last, compared to the same period of the prior year.
On the sales of contract manufacturing business, the sales resulted in exceeding prior year’s results byfocusing on getting contracts in oral drug sales, on top of injectable drug sales, since one of the biggest oral
drug plant in Japan was completed two years ago, and led by starting sell-in of new oral drugs and productionlines for steroidal and penem drugs.
As a result, net sales of this business were 28,775 million yen.
[3] Glass & Materials businessIn the field of glass materials, the sales of glass tube for pharmaceutical purpose performed steady as whole
thanks to the acquisition of the pharmaceutical glass tube manufacturing companies as subsidiaries, though
the domestic demands in glass tube for pharmaceutical purpose decreased. Furthermore, we established thebusiness of glass for pharmaceutical purpose in China and India and started the operation in overseas. The
export of glass for thermos bottles had showed temporarily the trend of recovery but the demands decreased atlast due to the sharp appreciation of the yen. As for the sales of glass for lighting purposes, the sales of glass
tube for electric lamp increased thanks to the good condition in domestic production for automobile, on theother hand the sales of glass tube for backlights decreased under the influence of penetration of LED products.
In the filed of other pharmaceutical container, the sales of rubber stopper for pharmaceutical use, container
for combination products, bags for antimicrobial agent and parts of pre-filled syringe increased steadily in thefirst and second quarter period, based on our plastics, metal and rubber processing technologies. However, inthe third quarter period ended December 31, 2010, the sales decreased slightly by the influence of inventory
adjustment by pharmaceutical companies.
As for the medicinal preparation and administration related device, we are advancing commercialization of
products by both of self-development and joint development with pharmaceutical companies so as to meet thediverse needs. Furthermore, we continue to promote contract manufacturing and development cooperating withdomestic and foreign pharmaceutical companies in general life cycle management of pharmaceuticals, entering
the development of combination products, systematization for self-injection and modification of dosage form in
the view.
As a result, net sales of this business were 17,982 million yen.
[4] Other businessIn the other business, the sales from real estate rental income were 314 million yen.
(2) Qualitative information on the consolidated financial position[1] Analysis concerning the conditions of assets, liabilities and net assets
Total assets increased 22,889 million yen from the end of the previous period to 406,286 million yen. Current
assets increased 14,927 million yen and noncurrent assets increased 7,962 million yen. Main reason for theincrease in current assets was that notes and accounts receivable-trade increased 7,552 million yen andmerchandise and finished goods increased 4,728 million yen. Main reason for the increase in noncurrent
assets was that machinery, equipment and vehicles increased 5,832 million yen and goodwill increased 10,713
million yen.
Total liabilities increased 22,842 million yen to 290,168 million yen. Current liabilities increased 8,043 million
yen and noncurrent liabilities increased 14,798 million yen. Current liabilities increased mainly due to theincrease of 10,767 million yen in Short-term loans payable and main reason for the increase in noncurrent
liabilities was that long-term loans payable increased 15,648 million yen.
Net assets increased 47 million yen to 116,118 million yen from the end of the previous period.
Shareholders’ equity increased 957 million yen and valuation and translation adjustments decreased 1,729
million yen.

-3-

[2] Analysis concerning the conditions of cash flows
The ending balance of cash and cash equivalents, hereinafter called Cash, in the period under review
decreased 1,886 million yen to 54,301 million yen.
The conditions and main factors of each cash flow during the period under review were as follows.
(Cash flows from operating activities)
Net Cash provided by operating activities was 10,497 million yen. The main accounts of Cash inflow wereincome before income taxes and minority interests, 9,581 million yen, depreciation and amortization, 14,746
million yen. The main accounts of Cash outflow were increase of notes and accounts receivable-trade 6,367
million yen, increase of inventories 6,924 million yen, and payment of corporate income tax, 8,117 million yen.
(Cash flows from investing activities)
Net Cash used in investing activities was 26,080 million yen. The main account of Cash outflow werepurchase of investment securities 10,905 million yen and purchase of noncurrent assets 13,257 million yen.
(Cash flows from financing activities)
Net Cash provided by financing activities was 12,493 million yen. The main accounts of Cash inflow were
proceeds from long-term loans payable, 37,743 million yen. The main accounts of Cash outflow were decreasein commercial papers, 10,000 million yen, and repayment of long-term loans payable, 15,864 million yen.
(3)Qualitative information concerning forecast of consolidated financial results
In the world economy in the future, U.S. economy is expected to recover gradually, on the other hand
economic activities in emerging countries and resource-rich country may bring price appreciation of natural
resource and food in the world economy. In the Japanese economy, impact of decreasing demands by theshrinking and aging population and sharp appreciation of the yen will remain the business environment more
severe.
Under such condition we aim to expand sales and production and improve its efficiency, and promote
manufacturing in each location on the basis of local production for local consumption so as to improve ourbusiness performance.
As for the forecast of consolidated financial results, we have not revise the forecast of consolidated financial
results for the fiscal year 2010 (Year ending March 31, 2011) which was published November 10, 2010.
2. Other information(1)Overview of changes in significant subsidiaries
N/A(2) Overview of accounting treatments simplified or unique for preparation[1] Simplified accounting procedures
1) Calculation of estimated impairment for general receivables
As it was accepted that there was no significant change between the actual rate or index of bad debts accrual
calculated at the end of the current quarterly consolidated accounting period and at the end of the previous
consolidated accounting year, the later rate or index was utilized for estimation of impairment of general
receivables.
2) Measurement for inventory
As for the inventory amount at end of the current quarterly consolidated accounting period, actual stock
counting procedure was omitted and the inventory amount was calculated by the reasonable method based on
the actual stock balance at end of the second quarter of this consolidated accounting year.

-4-3) Calculation method for depreciation of noncurrent assets
The noncurrent assets depreciated in declining balance method were calculated by prorating the depreciation
amount in the consolidated accounting year4) Deferred tax assets and liabilities
As for the judgment of collectability of deferred tax assets, the forecasted financial results and tax planning
used in the end of the previous consolidated accounting year was utilized, as it was accepted that there was no
significant change in the situation of accrued temporally differences from the end of the previous consolidated
accounting year.
[2] Accounting procedures unique for preparation of quarterly consolidated financial statements: N/A(3) Overview of changes in accounting principles, procedures, and disclosure for preparation[1] Change in accounting principles(Application of Revised Accounting Standard for Equity Method of Accounting for Investments)
Effective from the first quarter of fiscal year 2010, the Company has applied the Revised Accounting Standard
for Equity Method of Accounting for Investments (Accounting and Standards Board of Japan (ASBJ) Statement
No. 16, issued March 10, 2008) and the Practical Solution on Unification of Accounting Policies Applied to
Associates Accounted for Using the Equity Method (Practical Issues Task Force (PITF) No. 24, issued March
10, 2008). There is no impact on profit and loss regarding to this change.
(Application of Accounting Standard for Asset Retirement Obligations)
Effective from the first quarter of fiscal year 2010, the Company has applied the Accounting Standard for
Asset Retirement Obligations (ASBJ Statement No. 18, issued on March 31, 2008) and Guidance on
Accounting Standard for Asset Retirement Obligations (ASBJ Guidance No. 21, issued on March 31, 2008).
The impact of this change was to reduce both operating income and ordinary income by 9 million yen andincome before income taxes by 98 million yen.
(Application of Accounting Standards for Business Combinations)
Effective from the first quarter of fiscal year 2010, the Company has applied Accounting Standard forBusiness Combinations (ASBJ Statement No. 21), issued on December 26, 2008; Accounting Standard forConsolidated Financial Statements (ASBJ Statement No. 22), issued on December 26, 2008; Partial
Amendments to Accounting Standard for Research and Development Costs(ASBJ Statement No. 23), issued
on December 26, 2008; Revised Accounting Standard for Business Divestitures (ASBJ Statement No. 7,
revised 2008), issued on December 26, 2008; Revised Accounting Standard for Equity Method of Accounting
for Investments (ASBJ Standard No. 16, revised 2008), issued on December 26, 2008; and Revised Guidanceon Accounting Standard for Business Combinations and Accounting Standard for Business Divestures (ASBJ
Guidance No. 10, revised 2008),issued on December 26, 2008. There is no impact on profit and loss regarding
to this change.
(Additional Information)
The revision of retirement benefit scheme
The Company and the consolidated subsidiary company, Nipro Medical Industries Co., Ltd. had adopted theretirement benefit scheme framed by unfunded defined benefit pension plan and tax-qualified retirement
pension plan. However, from January 1st, 2011, the retirement benefit scheme is transferred to the scheme
framed by unfunded defined benefit plan, funded defined benefit pension plan and defined contribution pension
plan while the tax-qualified retirement pension plan was finished.
In accordance with this transfer, we resulted 453 million yen of “gain on revision of retirement benefit plan” asextraordinary gain, applying “Accounting standard for transfer between retirement benefit plans” (ASBJ
Guidance No.1).

-5-[2] Change in accounting principles(Overview of changes in significant consolidated subsidiaries)
As a result of the application of the Cabinet Office Ordinance Partially Revising Regulation on Terminology,
Forms and Preparation of Financial Statements (Cabinet Office Ordinance No.5, March 24, 2009) based on the
Accounting Standard for Consolidated Financial Statements (ASJB Statements No. 22 of December 26, 2008),
the item “Income before minority interests” is included in the financial statements in the current nine months
period.

-6-

3. Consolidated Financial Statements(1) [ Consolidated Balance Sheets ](Amount: million yen)

As ofDecember 31, 2010
AssetsCurrent assets
Cash and deposits
Notes and accounts receivable-trade
Merchandise and finished goods
Work in process
Raw materials and supplies
Deferred tax assets
Other
Allowance for doubtful accounts
Total current assets
Noncurrent assets
Property, plant and equipment
Buildings and structures
Accumulated depreciation and impairment loss
Buildings and structures, net
Machinery, equipment and vehicles
Accumulated depreciation and impairment loss
Machinery, equipment and vehicles, net
Land
Lease assets
Accumulated depreciation
Lease assets, net
Construction in progress
Other
Accumulated depreciation and impairment loss
Other, net
Total property, plant and equipment
Intangible assets
Goodwill
Lease assets
Other
Total intangible assets
Investments and other assets
Investment securities
Deferred tax assets
Guarantee deposits
Other
Allowance for doubtful accounts
Total investments and other assets
Total noncurrent assets
Total assets

-7-

As of
March 31, 2010

57,17963,85643,231
8,286
11,058
2,907
8,837
(501)
194,856

59,26656,30338,503
6,192
10,008
3,149
6,937
(432)
179,928

111,704(60,464)
51,239133,331(91,359)
41,971
19,826
1,495
(369)
1,126
10,832
26,977(21,957)
5,019
130,015

107,011(56,495)
50,515
117,534(81,395)
36,13819,766
1,393
(173)
1,220
11,99225,032(20,456)
4,575
124,208

11,275144
1,840
13,260

561
78
1,736
2,376

63,589
407
3,956
3,407
(3,206)
68,154
211,430
406,286

72,875
334
4,071
2,788
(3,186)76,883
203,468
383,396

(Amount: million yen)

As ofDecember 31, 2010
Liabilities
Current liabilities
Notes and accounts payable-trade
Short-term loans payable
Commercial papers
Current portion of bonds
Lease obligations
Accounts payable-otherAccrued directors' bonuses
Income taxes payable
Provision for bonuses
Provision for directors' bonuses
Provision for loss on business liquidation
Notes payable-facilities
Other
Total current liabilities
Noncurrent liabilities
Bonds payable
Convertible bond-type bonds
with subscription rights to shares
Long-term loans payable
Lease obligations
Deferred tax liabilities
Provision for retirement benefits
Provision for directors' retirement benefits
Provision for loss on litigation
Other
Total noncurrent liabilities
Total liabilities
Net assets
Shareholders' equity
Capital stock
Capital surplus
Retained earnings
Treasury stock
Total shareholders' equity
Valuation and translation adjustments
Valuation difference on available-for-sale securities
Foreign currency translation adjustment
Total valuation and translation adjustments
Minority interests
Total net assets
Total liabilities and net assets

-8-

As of
March 31, 2010

34,37375,21010,050
340
5,969
1,203
1,347
114
1,954
7,326
8,358
146,248

29,20364,442
10,00010,160
318
5,792
204
4,932
1,758
23
1,954
3,869
5,543
138,204

28,00028,00015,00015,00088,488
1,020
7,388
1,555
633
170
1,664
143,920
290,168

72,839
1,098
7,771
1,972
614
170
1,655
129,121267,325

28,66329,972
48,178(863)
105,590

28,66329,972
47,219(862)
104,993

14,100(6,514)
7,586
2,581
116,118
406,286

15,024(5,708)9,316
1,761
116,070
383,396(2) [ Consolidated Statements of Income ](Amount: million yen)

Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating income
Non-operating income
Interest income
Dividends income
Other
Total non-operating income
Non-operating expenses
Interest expenses
Depreciation
Foreign exchange losses
Equity in losses of affiliates
Other
Total non-operating expenses
Ordinary income
Extraordinary income
Gain on sales of noncurrent assets
Compensation income
Surrender value of insurance
Licensed dealership charges
Gain on revision of retirement benefit plan
Other
Total extraordinary income
Extraordinary loss
Loss on retirement of noncurrent assets
Abnormal manufacturing cost
Corresponding loss to compensation income

Nine months ended
December 31, 2009
133,063
93,642
39,421
24,653
14,767

Nine months ended
December 31, 2010
145,223
101,200
44,022
29,736
14,286

175
598
534
1,308

248
654
286
1,190

1,694
166
534
1,055
121
3,571
12,503

1,768
3,367
176
205
5,517
9,959

23
193
109
26
352

15
122
300
453
85
976

53
486
190

97
159
-

159

-

142
1,031
11,824
5,521
(295)
5,225
246
6,352

906
190
1,353
9,581
4,214
968
5,183
4,398
395
4,002

Loss on voluntary product recall
Loss on liquidation of business
Other
Total extraordinary losses
Income before income taxes and minority interests
Income taxes-current
Income taxes-deferred
Total income taxes
Income before minority interests
Minority interests in income
Net income-9-(3) [ Consolidated Statements of Cash Flows ](Amount: million yen)
Nine months ended
December 31, 2009
Net cash provided by (used in) operating activities
Income before income taxes and minority interests
Depreciation and amortization
Impairment loss
Amortization of goodwill
Equity in (earnings) losses of affiliates
Increase (decrease) in allowance for doubtful accounts
Interest and dividends income
Interest expenses
Foreign exchange losses (gains)
Decrease (increase) in notes and accounts receivable-trade
Decrease (increase) in inventories
Increase (decrease) in notes and accounts payable-trade
Decrease (increase) in other assets
Increase (decrease) in other liabilities
Other loss (gain)
SubtotalInterest and dividends income received
Interest expenses paid
Other proceeds
Other payments
Income taxes paid
Net cash provided by (used in) operating activities
Net cash provided by (used in) investing activities
Payments into time deposits
Proceeds from withdrawal of time deposits
Purchase of investment securities
Purchase of Investments in subsidiaries resulting inchange in scope of consolidation
Purchase of noncurrent assets
Proceeds from sales of noncurrent assets
Proceeds from governmental subsidies
for investment in property and equipment
Net decrease (increase) in short-term loans receivable
Payments of loans receivableCollection of loans receivable
Other payments
Other proceeds
Net cash provided by (used in) investment activities- 10 -

Nine months ended
December 31, 2010

11,824
13,401
220
1,055
1
(773)
1,694
32
(9,286)(2,558)
5,060
230
(765)
(76)
20,059882(1,507)763(425)(4,091)
15,681

9,581
14,746
26
1,841
176
140
(903)
1,768
310
(6,367)(6,924)
6,734(1,299)(1,467)531
18,896914(1,569)669(296)(8,117)
10,497(1,679)1,604(8)(2,304)
2,481(10,905)-(632)(22,947)55(13,257)
46

202

25

343

(490)
(413)
11
(641)
0
(26,080)-0-2(22,427)

(Amount: million yen)
Nine months ended
December 31, 2009
Net cash provided by (used in) financing activities
Net increase (decrease) in short-term loans payable
Increase (decrease) in commercial papers
Proceeds from long-term loans payable
Repayment of long-term loans payable
Proceeds form issuance of bonds
Redemption of bonds
Decrease (increase) in treasury stock
Repayments of finance lease obligations
Cash dividends paid
Cash dividends paid for minority shareholders
Other payments
Net cash provided by (used in) financing activities
Effect of exchange rate change on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Increase in cash and cash equivalentsfrom newly consolidated subsidiary
Cash and cash equivalents at end of period- 11 -

Nine months ended
December 31, 2010

12,83910,00017,777(13,560)
2,982(17,120)(11)(152)(1,477)(2)(21)
11,254(494)(4,014)45,352

4,026(10,000)
37,743(15,864)
(110)
(3)
(266)
(3,023)(3)(6)
12,493(391)(3,481)
56,188-

1,595

49,36654,301

(4) Notes related to going concern
N/A(5) Segment information<Segment information by business category>Nine months ended December 31, 2009

(Millions of yen)

MedicalEquipment

Pharmaceutical

Glass &
Materials(1)Sales to third parties

82,806

43,1266,485645(2)Inter-segment sales
and transfers

-

0

3,079

82,806

43,126

14,045

4,037

Eliminations/Corporate

Consolidated

133,063-

133,06370

3,149(3,149)

-

9,564

715

136,213(3,149)133,063

1,417

70

19,571(4,803)

14,767

Other

Total

Net sales

Total
Operating income

Notes: 1. Classification of business categories and main products in each business category
Business categories are classified based on the proximity in terms of purposes andmanners of usage of the products in the market.
Main products belonging to each business category are as follows:Business
category
MedicalEquipment

Main products and commodities
Dialyzers, blood tubing sets, injection needles, syringes, and infusion sets,
etc.

Pharmaceutical

Half-type and full-type kits, double-bag kits, pre-filled syringes, dialysis
solution, and circulatory drugs, etc.

Glass & Materials

Glass for pharmaceutical containers, glass for thermos bottles, glass forlighting purposes, stoppers for plastic containers and rubber stoppers, etc.

Other

Machinery for manufacture of medical equipment and real estate rental
income, etc.

- 12 -

<Segment information by geographical area>
Nine months ended December 31, 2009
Japan

(Millions of yen)

America

Asia

EuropeTotal

Eliminations/Corporate

Consolidated

Net sales(1) Sales to third parties

104,723

13,209

9,613

5,517

133,063-

133,063(2) Inter-segment sales
and transfers

22,356488

311,43934,287(34,287)-

Total

127,079

13,697

9,616

16,956167,351(34,287)

133,063

Operating income (loss)

18,301

(49)

78

1,652

19,982(5,214)

14,767

Notes:

1.

Classification of countries or areas is based on geographical proximity.

2.

The major countries included in each geographical area are as follows:
America……..
Europe………
Asia………….

The United States of America and Brazil
Belgium
China, Thailand and Singapore<Overseas sales>
Nine months ended December 31, 2009

1. Overseas sales(Millions of yen)

America

Europe

Asia

Total

21,121

15,226

7,744

44,092

2. Consolidated net sales
3. Percentage of overseas sales toconsolidated net sales (%)

Notes:

133,063

15.9％

11.4%

5.8％

33.1％

1.

Overseas sales represent those of the Company and the consolidated subsidiaries to countries
and areas outside of Japan.

2.

Classification of countries or areas is based on geographical proximity.

3.

The major countries included in each geographical area are as follows:
America ·······
Europe·········
Asia ·············The United States of America, Canada and Brazil
Belgium, Denmark and Germany
China, India, Indonesia, Taiwan and Thailand- 13 -

<Segment information>
1. Outline of reportable operating segments
The reportable operating segments are components of an entity for which separate financial information isavailable and evaluated regularly by the board of director in determining the allocation of management
resources and in assessing performance.
We currently operate our business on a stand-alone basis with the divisional organization and evaluate theperformance of sales and manufacture of each division regardless of their products. Accordingly, we divide ouroperations into 3 reportable operating segments on the basis of its main products: Medical, Pharmaceuticals
and Glass & Materials.
*MedicalDomestic division sells injection- and infusion-related products, artificial organ-related products,
highly functional products, dialysis-related products and diabetic-related products.
In the international division, head office plays the center role and place overseas sales andmanufacturing base for medical equipment and sales injection- and infusion-related products,
artificial organ-related products and diabetic-related products.
*Pharmaceutical
Mainly, domestic subsidiaries sell and manufacture injectable drug, oral drugs and products bycontract manufacturing like combination products (Kit injectable).
*Glass & Materials
In the field of glass for pharmaceutical purposes, we sell glass for glass tube, glass forampoule. In the field of glass & materials products, we sell glass for thermos bottles and glass forlighting purpose. In addition, we sell container for combination products and undertake thecontract sales of pharmaceuticals related to the container for combination products frompharmaceutical company.
2. Sales and profit by reportable operating segments
Nine months ended December 31, 2010

(Millions of yen)Segment

Medical

Other
Note.1

Total

Adjustment
Note.2

Consolidated
statements ofincomeNote.3

Pharmaceutical

Glass &
Materials

Total

28,775

17,982

144,908314

145,223-

145,223

13,4482,938

16,51732

16,550(16,550)-

Net sales(1)Sales to third parties 98,150(2)Inter-segment sales
141
and transfers
Total

98,29242,223

20,910161,426

347

161,774(16,550)

145,223

Segment profit

14,540

1,888

2,002

18,432

66

18,498(4,211)

14,286

Notes:

1.
2.

3.

“Other” is the business segment which is not included in the reporting segment and consist ofreal estate income and sales by headquarter.
Adjustment for the segment profit of (4,211) million yen includes elimination of inter-segment
transaction of 255 million yen and corporate cost of (4,467) million yen. Corporate cost consisted
primarily of sales, general and administrative expenses and research and development costwhich do not belong to the reporting segment.
Segment profit is adjusted to the operating income on the consolidated statements of income.

3. Information on goodwill by reportable operating segments(Significant variation in the amount of goodwill)
We included the Nipro Diagnostics, Inc. and other 3 companies in the scope of consolidation.
The regarding increase in the amount of goodwill was 10,543 million yen compared with the endof the previous year.

- 14 -

(Additional information)
Effective from the first quarter ended June 30, 2010, we have applied the revised AccountingStandard for Disclosures about Segments of an Enterprise and Related Information (ASBJ Statement
No. 17, issued March 27, 2009) and Guidance on Accounting Standard for Disclosures about
Segments of an Enterprise and Related Information (ASBJ Guidance No. 20, issued March 21, 2008).

(6)Notes to statements of shareholders’ equity, if having significant variation
N/A- 15 -